Pfizer v. Apotex: Xeljanz XR Patent Suit Dismissed Without Prejudice
Pfizer and its affiliates filed a patent infringement action against Canadian generic manufacturer Apotex in the Delaware District Court, asserting reissue patent USRE041783E covering tofacitinib extended-release tablets marketed as Xeljanz XR. The case closed in 119 days — before Apotex filed any answer — with Pfizer voluntarily dismissing all claims without prejudice, preserving its right to refile.
Pfizer’s Pre-Answer Withdrawal Keeps Tofacitinib XR Dispute Open
On June 23, 2025, Pfizer Inc. together with co-plaintiffs C.P. Pharmaceuticals International C.V., PF PRISM C.V., PBG Puerto Rico LLC, and PF PRISM IMB B.V. filed a patent infringement action in the District of Delaware against Apotex Inc. The suit asserted reissue patent USRE041783E in connection with Apotex’s proposed generic version of Pfizer’s Xeljanz XR — 11 mg and 22 mg tofacitinib citrate extended-release tablets used in the treatment of inflammatory conditions including rheumatoid arthritis and ulcerative colitis.
On October 20, 2025 — 119 days after filing — Pfizer filed a Notice of Dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i), dismissing all claims without prejudice. The notice explicitly confirmed that Apotex had not yet served an answer or a motion for summary judgment, which is the procedural prerequisite for a plaintiff to exercise this unilateral right of dismissal. Critically, a without-prejudice dismissal leaves the underlying claims legally intact: Pfizer may refile the same infringement action in the future if circumstances warrant.
The sub-120-day lifespan and pre-answer timing suggest the dismissal may reflect ongoing ANDA-related negotiations, a settlement framework still being formalised, or a strategic recalibration of Pfizer’s enforcement approach — the public record is silent on the precise driver. What is notable is that Pfizer committed multiple affiliated entities across the complaint, suggesting a coordinated global IP enforcement posture around the Xeljanz XR franchise. The without-prejudice preservation of rights means this dispute cannot be considered resolved, and monitoring for refiling or related ANDA litigation activity remains advisable.
Filing to Dismissed without Prejudice in 119 days
119 days — resolved before defendant answered, faster than typical Hatch-Waxman first-instance timelines
Dismissed without prejudice: what Pfizer’s Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): the plaintiff’s unilateral exit right
Under Federal Rule of Civil Procedure 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order by filing a notice of dismissal before the opposing party serves an answer or a motion for summary judgment. Apotex had done neither, so Pfizer exercised this right unilaterally. The court plays no gatekeeping role here — the dismissal is self-executing upon filing. No merits determination was made.
No court order requiredWithout prejudice: the case is closed but not concluded
A dismissal without prejudice means the plaintiff’s claims are not adjudicated on their merits and are not barred by res judicata. Pfizer retains the legal ability to refile the same infringement claims under USRE041783E against Apotex. This contrasts sharply with a with-prejudice dismissal, which would extinguish those claims permanently. The public record does not disclose whether any settlement, licence, or standstill agreement underpins this dismissal.
Pfizer may refileApotex faces lingering patent exposure on tofacitinib XR
For Apotex, the without-prejudice dismissal provides no confirmed freedom to operate. The infringement allegation tied to USRE041783E has not been challenged, invalidated, or resolved. Apotex’s ANDA pathway for generic tofacitinib XR tablets remains legally exposed to a refiled suit. Without a licence or consent decree on record, commercial launch carries the risk of triggering renewed litigation, potentially with a new automatic 30-month stay under Hatch-Waxman.
No FTO confirmedXeljanz XR generic entry remains uncertain in the near term
Tofacitinib is a high-value JAK inhibitor franchise. Pfizer’s decision to withdraw before substantive litigation costs accrued, yet without prejudice, is consistent with a holding pattern around commercial strategy or parallel negotiations. For other generic manufacturers monitoring ANDA pathways for tofacitinib XR, this dismissal does not signal a cleared path — USRE041783E remains in force and Pfizer’s multi-affiliate enforcement structure suggests continued vigilance over the formulation estate.
Patent remains enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pfizer, Inc. | Company | Global biopharmaceutical company — holder of USRE041783E covering tofacitinib XR formulationsSearch in Eureka ↗ |
| Defendant | Apotex, Inc. | Company | Canadian generic pharmaceutical manufacturer seeking U.S. market entry with generic tofacitinib XR tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice strictly tracks the Rule 41(a)(1)(A)(i) precondition, reciting on the face of the filing that Apotex had not yet answered. This phrasing is legally significant: it forecloses any argument that court approval was required and makes the dismissal self-effectuating. The without-prejudice designation means no claim preclusion attaches. From Pfizer’s perspective, the filing preserves the full value of USRE041783E; from Apotex’s perspective, the infringement allegation remains unresolved and commercially constraining.
USRE041783E — Tofacitinib Extended-Release Tablet Formulation
USRE041783E is a United States reissue patent — a designation that signals the original patent was subsequently corrected or broadened through a reissue proceeding before the USPTO. The underlying application number is US12/577790, placing the original filing in the 2009 timeframe consistent with Pfizer’s development of the extended-release formulation of tofacitinib citrate. Tofacitinib is a Janus kinase (JAK) inhibitor approved for multiple inflammatory indications; the XR formulation enables once-daily dosing at 11 mg and 22 mg doses, commercially marketed as Xeljanz XR.
Reissue patents occupy a strategically sensitive position in pharmaceutical IP portfolios: the reissue process can both correct errors and adjust claim scope, meaning competitors must analyse both the original patent and the reissue prosecution history to understand enforceable claim boundaries. For ANDA filers targeting Xeljanz XR, USRE041783E represents a formulation-level barrier that cannot be designed around simply by using the same active ingredient at a different dose. The patent’s continued enforceability post-dismissal means any generic developer seeking Paragraph IV certification against this patent faces the near-certainty of Hatch-Waxman litigation and a potential 30-month stay.
Should your team run an FTO analysis against USRE041783E?
Any R&D team or generic manufacturer developing extended-release oral formulations containing tofacitinib citrate — or functionally comparable JAK inhibitor XR delivery systems — should treat USRE041783E as a live freedom-to-operate risk. The without-prejudice dismissal of Pfizer v. Apotex confirms the patent is actively monitored and enforced; Pfizer’s multi-entity plaintiff structure suggests it is prepared to litigate across jurisdictions. Even developers not yet at ANDA stage should assess whether early formulation decisions create future exposure under the reissue claims.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of USRE041783E against your specific formulation parameters — identifying both the reissue claims and any related continuations or divisionals in the Xeljanz XR patent family. Eureka’s prosecution history analysis surfaces the reissue amendments that define the outer boundary of enforceable claim scope, giving your IP and regulatory teams the precision needed for Paragraph IV certification strategy or design-around planning.
Run a freedom-to-operate analysis on USRE041783E to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Tofacitinib and JAK Inhibitor Patent Cases
Cases below involve comparable ANDA-triggered pharmaceutical patent infringement actions in the Delaware District Court concerning JAK inhibitor and extended-release oral formulation patents.
What this case signals for the tofacitinib and JAK inhibitor IP landscape
Pfizer’s pre-answer withdrawal preserves maximum strategic optionality — a pattern worth tracking across the Xeljanz franchise.
Without-prejudice dismissals are enforcement tools, not concessions
Pfizer’s Rule 41(a)(1)(A)(i) exit before Apotex answered costs Pfizer nothing legally. The patent is unimpaired, the claim is preserved, and Pfizer avoided any risk of early adverse rulings or invalidity counterclaims. Generic challengers should not treat this dismissal as a weakening of the patent position.
ANDA litigants: monitor USRE041783E for refiling signals
Any generic manufacturer with an ANDA referencing tofacitinib XR formulations should track USRE041783E closely. The reissue designation indicates the patent has already been substantively amended post-grant, which may affect claim scope analysis — but the patent remains live and assertable. A PatSnap alert on this number is a low-cost early warning mechanism.
Pfizer v Apotex — key questions answered
The public record does not disclose the reason. Pfizer filed a Rule 41(a)(1)(A)(i) notice of dismissal, which requires no stated justification. The without-prejudice designation preserves Pfizer’s right to refile. Possible drivers include settlement negotiations, a licensing framework being finalised, or a tactical recalibration — none of which is confirmed in court filings.
A without-prejudice dismissal does not grant Apotex freedom to operate. USRE041783E remains in force and Pfizer’s infringement claims are unresolved. Apotex cannot rely on this dismissal as a defence in any future suit. If Apotex proceeds toward commercial launch, Pfizer could refile and potentially trigger a new 30-month automatic stay under Hatch-Waxman.
USRE041783E is a USPTO reissue patent based on application US12/577790, covering tofacitinib extended-release tablet formulations. Reissue patents have been subject to post-grant amendments, which creates prosecution history estoppel considerations. Challengers must analyse both original and reissue prosecution histories when constructing invalidity or non-infringement arguments — this adds complexity relative to standard utility patents.
The case was filed in the United States District Court for the District of Delaware, Case No. 1:25-cv-00775, before Judge Colm F. Connolly. Delaware is the predominant venue for Hatch-Waxman pharmaceutical patent litigation in the United States. The case closed on October 20, 2025 following Pfizer’s voluntary dismissal without prejudice.
Yes. Because the dismissal was expressly without prejudice under Rule 41(a)(1)(A)(i), no claim preclusion or res judicata applies. Pfizer may refile the same infringement claims under USRE041783E against Apotex at any time, subject to applicable statutes of limitations. The dismissal carries no legal bar to a subsequent action on the same patent and same product.
PatSnap Eureka searches patents and litigation data to answer instantly.